Share via:
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.
What we still don’t know about weight-loss drugs
Weight-loss drugs have been back in the news this week. First, we heard that Eli Lilly, the company behind Mounjaro and Zepbound, became the first healthcare company in the world to achieve a trillion-dollar valuation.
But we also learned that, disappointingly, GLP-1 drugs don’t seem to help people with…
We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.
What we still don’t know about weight-loss drugs
Weight-loss drugs have been back in the news this week. First, we heard that Eli Lilly, the company behind Mounjaro and Zepbound, became the first healthcare company in the world to achieve a trillion-dollar valuation.
But we also learned that, disappointingly, GLP-1 drugs don’t seem to help people with…
We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi
